A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Markus Renschler, MD
Celgene Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California San Diego
La Jolla, California, United States
- Sarcoma Oncology Center
Santa Monica, California, United States
- Indiana University Cancer Pavilion
Indianapolis, Indiana, United States
- James Graham Brown Cancer Center
Louisville, Kentucky, United States
- Sinai Hospital of Baltimore- Alvin and Lois Lapidus Cancer Institute
Baltimore, Maryland, United States
- Montefiore Medical Center
The Bronx, New York, United States
- Ut Health Science Center at San Antonio- Cancer Therapy and Research Center
San Antonio, Texas, United States
- Hunstman Cancer Institute
Salt Lake City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Jun 2009
- Primary completion
- 1 May 2011
- Completion
- 1 May 2011
- Last update posted
- 1 Nov 2019
- Registered enrollment
- 24
- Registry id
- NCT00915083
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.